Although the average maintenance warfarin dose is 4 to 6 mg/d, there is a very wide range of doses required to achieve the same INR among individuals, varying by as much as 20-fold
While these medications may seem similar at first glance, they have distinct differences in terms of efficacy, dosage, and approved uses
The MHRA's Yellow Card scheme continues to monitor post-marketing safety data, including any reports of pancreatic malignancy
Tidmarsh announces, then retracts, surrogate endpoint review George Tidmarsh, Director of CDER, posted that while surrogate endpoints have accelerated treatments, they also risk failures in confirmatory trials
Managing missed doses appropriately is important for maintaining therapeutic benefits while avoiding adverse effects from irregular dosing patterns